the aid library

LIST OPTIONS

Filter

5899

Optimizing active case-finding for tuberculosis

World Health Organization. Regional Office for South-East Asia (2021) C_WHO

he WHO South-East Region in 2019 accounted for nearly a million missing TB patients from the estimated incidence. Active case-finding (ACF) or systematic screening for tuberculosis is an important tool to reach out to missing TB patients. When appropriately implemented, the activity is cost effectiv... more

Download (1206)

View PDF (786)

Health Care Waste Management Manual, Fourth Edition

Department of Health Philippines (2020) CC

This document shall serve as the most comprehensive set of guidelines on the safe management of waste generated from heath care activities in the country. It incorporates the requirements of all Philippine laws and regulations governing HCWM and is designed for the use of individuals, public and pri... more

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ... more

HIV & COVID-19

Reijer, P.; and S. Mauder (2021) CC

MEDBOX Issue Brief no.18. The MEDBOX team has compiled a new issue brief on the impact of COVID-19 on PLHIV HIV prevention programmes and treatment for this year's World AIDS Day on 1 December 2021.

Strategic plan towards ending TB in the WHO South-East Asia Region: 2021–2025

World Health Organization (WHO), Regional Office for South-East Asia (2021) C_WHO

The WHO End TB Strategy aims to end the global TB epidemic by 2030, in alignment with Goal 3 of the United Nations (UN) Sustainable Development Goals (SDGs). Member States of the World Health Organization (WHO) and the UN committed to ending the TB epidemic through adoption of WHO’s End TB Strateg... more

Download (92)

View PDF (146)

Evaluation of the Affordable Medicines Programme in Ukraine

World Health Organization WHO, Regional Office of Europe (2019) C_WHO

This report reviews and analyses the Affordable Medicines Programme, which was introduced in Ukraine in April 2017 to provide patients with improved access to 23 outpatient medicines for the treatment of chronic noncommunicable diseases. The evaluation combines both quantitative and qualitative anal... more

Download (134)

View PDF (158)

Tuberculosis in the Americas. Regional Report 2020

Pan American Health Organisation PAHO (2021) C_WHO

This regional report on the situation of tuberculosis (TB) in the Americas contains information from 2019, provided by the countries of the Region through the World Health Organization TB data collection system. These data have been consolidated and analyzed at the regional level. In addition to pre... more

Download (177)

View PDF (227)

Global tuberculosis report 2022
recommended

World Health Organization WHO (2022) C_WHO

The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets. ... more

External Link

The Road to 2030 - Advocacy brief: Progress and challenges

World Health Organization WHO Team Control of Neglected Tropical Diseases (2022) C_WHO

In January 2021, the World Health Organization (WHO) published a new road map to address the burden of disease and death imposed by neglected tropical diseases (NTDs). The end of the first year of the 2021-2030 NTD road map is an opportunity to take stock of where we stand and how we plan to move fo... more

External Link

Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review

Medina-Rincón, G.; Gallo-Bernal, S.; Jiménez, P.; et al. (2021) CC

Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493 .Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech... more

External Link

Chagas Clinical Research Platform Newsletter

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f... more

External Link

Clinical Presentation of T.b. rhodesiense Sleeping Sickness in Second Stage Patients from Tanzania and Uganda

Kuepfer, I.; Hhary, EP.; Mpairwe, A.; Edielu, A.; Burri, C.; Blum, JA. PLOS Neglected Tropical Diseases (2011) CC

A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d... more

Download (116)

View PDF (166)

Gambiense human African trypanosomiasis: the bumpy road to elimination

Hasker E, Hope A, Bottieau E. Wolters Kluwer Health, Inc. (2022) C2

Gambiense human African trypanosomiasis is a deadly infectious disease affecting West and Central Africa, South Sudan and Uganda, and transmitted between humans by tsetse flies. The disease has caused several major epidemics, the latest one in the 1990s. Thanks to recent innovations such as rapid di... more

Download (185)

View PDF (210)

WHO pharmaceuticals newsletter - No. 1, 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world. In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f... more

National Guidelines for Glaucoma Eyecare

Ministry of Health Malawi (2021) CC

Glaucoma is a leading cause of irreversible blindness globally. In Malawi, glaucoma accounts for 15.8% of the blindness among people aged 50 years and above. Blindness from glaucoma is preventable with early detection and timely treatment. However, glaucoma management remains a challenge to eye care... more

Download (152)

View PDF (171)

West & Central Africa HIV catch-up - WHO in an era of transformation

World Health Organisation (WHO) (2023) C_WHO

The Transformation Agenda (TA) ushered in an ambitious reform process intended to transform the World Health Organization (WHO) into an organization that is proactive, results-driven, accountable and which meets stakeholder expectations, towards transforming and improving public health services in t... more

Download (286)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Fully fiund the global fund: Get back on track to ende AIDS, TB and Malaria in a Covid world

Global Fund Advocates Network (2021) CC

In 2019, the Global Fund’s 6th Replenishment raised more than $USD14 billion to fight HIV, Tuberculosis and Malaria. Just two years later, the world has changed significantly. Put simply: COVID-19 devastated prevention and treatment programs. For the first time since the Global Fund’s founding, ... more

Management of Type 2 Diabetes Mellitus

Richardson, C.R.; Borgeson, J. R.; Harrison, V.; et al. National Library of Medicine (2021) CC2

The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio... more

Rational Use of Inhaled Medications for the Patient with COPD and Multiple Comorbid Conditions: Guidance for Primary Care

Tisiligianni, I.; Hoines, K.; Jensen, C.; et al. International Primary Care Respiratory Group (IPCRG) (2019) CC2

The document discusses the complexities of managing patients with COPD and multiple comorbidities, highlighting the importance of personalized care and the appropriate use of inhaled corticosteroids (ICS). It outlines common comorbidities, such as asthma, osteoporosis, and diabetes, and offers guida... more

Therapeutics and COVID-19: living guideline (Arabic) recommended

Global tuberculosis report 2022 recommended

Therapeutics and COVID-19: living guideline (Arabic)
recommended

Global tuberculosis report 2022
recommended